Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

SOPHIA ANTIPOLIS, France, Nov. 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that results from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the 71st annual meeting of the American College of Rheumatology (ACR), in Boston, Massachusetts (see NOTE). Naproxcinod is NicOx' lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide Donator (CINOD) class. The presentation contained additional efficacy data to the top-line results announced in 2006 (see press release of October 27, 2006) which showed that naproxcinod met all three co-primary endpoints of the trial. The data showed that both doses of naproxcinod (750 mg and 375 mg bid) had superior efficacy to placebo at all time points (2, 6 and 13 weeks). This presentation also contained additional safety and tolerability information, including the gastro-intestinal adverse event rates and blood pressure measurements reported for each of the treatment groups.

Detailed clinical data from the 301 study were presented, including data for each of the three co-primary efficacy endpoints: WOMAC(TM) pain subscale, WOMAC(TM) function subscale and patients' overall rating of disease status. Each of the active treatments (naproxcinod 750 mg, naproxcinod 375 mg and naproxen 500 mg bid) were statistically significantly superior to placebo (p<=0.0002) at 2, 6 and 13 weeks. In addition, standard quality of life scores showed a functional improvement for both naproxcinod doses, as well as for the naproxen group.

At week 13, both doses of naproxcinod (750 mg and 375 mg bid) showed a slight decrease in systolic blood pressure in terms of the mean change from baseline compared to placebo (0.8 and 0.2 mmHg, respectively), while a 2 mmHg increase was observed for naproxen compared to placebo. Patients' blood pressure was measured by a health care professional using
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Research and Markets ... Chinese Aseptic Packaging Industry Report 2014" report to ... The Global and Chinese Aseptic Packaging Industry ... current state of the global Aseptic Packaging industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3
... Okla., March 9, 2011 Sandra Smith filed suit today ... over a failed hip replacement system from Johnson & Johnson, ... market.  John David Hart of the Law Offices of John ... Ms. Smith. Smith, of Yukon, underwent surgeries ...
... Inc. (NYSE: WST ) today announced that management ... Miami, FL.  Management will present an overview of West,s business ... ET. A live audio webcast of the Company,s ... will be accessible from the Company,s website at www.westpharma.com/en/investors ...
Cached Medicine Technology:Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device 2
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... jockeying for supremacy within a cancerous tumor, the most ... fastest, researchers at Dana-Farber Cancer Institute report in a ... journal Nature . The findings have important ... the study authors explained: Doctors need to ascertain which ... metastasis and select drugs that target the critical genes ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... Shabaikai is an ambitious historical novel, which ... Indians located on the shores of Russian River in ... ‘crooked snake’. Clarkson takes the reader into 20th Century ... prohibition and organized crime, providing a glimpse into the ... powerful men in the world convene the last two ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... The FDA has warned the consumer against the multiple ... issued after the FDA learned about the 24 related ... ,The FDA received information that counterfeit versions of ... web sites. Xenical manufactured by Hoffman-La Roche, Inc. help ...
... but new studies have revealed that coffee can be quite beneficial. ... cancers too. Some experts believe that it can also lower the ... ,Antioxidants in coffee help control the cell damage that can ... source of chlorogenic acid, which has been shown in animal experiments ...
... genes by American scientists has revealed a startling find. Around ... that is linked to// the risks of developing heart diseases. ... that is connected with diabetes. ,The findings, ... so many people have heart disease even if they do not ...
... countries met Friday to formally adopt a 24-page report on ... five days of heated debate to reaching a consensus on ... Friday," said Carloa Traverso Saibante, information officer for the UN ... IPCC report is formally adopted, it will be released to ...
... to mobilise US congressmen and senators against Indian authorities denying ... a case relating to his crusade against the corrupt healthcare ... of alleged wrongful treatment in India in May 1988, said: ... in US and will ask them to raise this issue ...
... Brazil government is up against giant drug manufacturers- Merck &Co. ... to the Brazilian government, there is no call to charge ... when Thailand is paying 65 cents for the same. ... last November. Last week the government declared the drug a ...
Cached Medicine News:Health News:New Health Drink—Coffe 2Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:Climate Talks Reach Consensus in Bangkok 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2
... quality patient care., ,S/5 Anesthesia Delivery ... anesthesia delivery. As part of the S/5 ... electronically controlled gas delivery and agent vaporization ... create a truly integrated system. The S/5 ...
... filler and Tegagel hydrogel wound filler ... specially formulated to help provide a ... to enhance wound healing. The unique, ... for management of non-draining, minimally draining ...
... SS is a complete physician preference card ... management system for all the supply management ... preference card system combined with a broad ... entire case cart and operating suite supply ...
Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand....
Medicine Products: